A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients
Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether tasisulam acts as an inducer of CYP3A using
midazolam as a sensitive and specific probe substrate of CYP3A.
The study will also assess the safety and tolerability of tasisulam and midazolam given in
combination and document any antitumor activity with tasisulam.